A study suggests that the availability of orphan drugs varies significantly between different...
- Research shows differences in orphan drug availability in Europe
- Tracing the story of mumps: a timeline
- World Malaria Day 2018: to achieve eradication, malaria transmission must be stopped
- World Malaria Day: WHO spotlights global health campaign
- The late-stage type 2 diabetes pipeline is dominated by ‘me-too’ drugs
Nektar and Takeda to test combination regimen for cancer
Nektar Therapeutics has entered into a clinical collaboration to investigate its NKTR-214 drug candidate in combination with Takeda Pharmaceutical’s TAK-659 for various types of cancer.
Research shows differences in orphan drug availability in Europe
A study suggests that the availability of orphan drugs varies significantly between different countries in Europe.
World Malaria Day 2018: to achieve eradication, malaria transmission must be stopped
On 25 April, the World Health Organization (WHO) member states celebrate World Malaria Day. This year’s theme, ‘Ready to Beat Malaria’, highlights the collective goal of the global malaria community – a malaria-free world.
World Malaria Day: WHO spotlights global health campaign
World Malaria Day, an annual event that recognises global efforts to control malaria, takes place on 25 April. This year, the World Health Organisation (WHO), along with partner organisations, is promoting the theme ‘Ready to Beat Malaria’, calling for greater investment to get the eradication of malaria back on track after the number of global malaria cases stopped falling for the first time in ten years.
The late-stage type 2 diabetes pipeline is dominated by ‘me-too’ drugs
Type 2 diabetes (T2D) is a chronic disease characterised by insulin resistance and pancreatic β-cell failure, with an underlying genetic predisposition that is heavily influenced by diet and lifestyle.
Tweaking diabetes treatments can improve effectiveness
Research carried out by Imperial College London has showed that small alterations to existing diabetes treatments can increase their effectiveness by changing their interactions with cells.
Tremfya approval: increasing options for psoriasis treatment
Johnson & Johnson’s (J&J) Tremfya (guselkumab) has recently been granted approval for the treatment of adults suffering from moderate-to-severe plaque psoriasis in Australia, Brazil, and Japan. J&J has licensed Tremfya to MorphoSys in these respective regions.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.